article thumbnail

RCE Technologies, Inc. Announces First-In-Human Transdermal Continuous Cardiac Biomarker Monitoring

DAIC

(RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection. RCE) is an innovative artificial intelligence (AI) based medical technology company dedicated to early heart attack detection. Featured in an ACC.24 Dohad , MD, as principal investigator.

article thumbnail

New 'Atherosclerosis Atlas' Sheds Light on Heart Attacks, Strokes

DAIC

MILLER, PHD, LED THE DEVELOPMENT OF A NEW "ATHEROSCLEROSIS ATLAS" THAT DETAILS, AT THE LEVEL OF INDIVIDUAL CELLS, CRITICAL PROCESSES RESPONSIBLE FOR FORMING THE HARMFUL PLAQUE BUILDUP THAT CAUSES HEART ATTACKS, STROKES AND CORONARY ARTERY DISEASE. When they break loose, they can be deadly, triggering strokes and heart attacks.

article thumbnail

Biomarker found to help identify cells that can repair damaged blood vessels

Science Daily - Heart Disease

Their findings could lead to new therapies for people with endothelial dysfunction, a type of disorder that contributes to coronary artery disease that may occlude with plaque and lack ability to carry sufficient blood into the heart tissue causing a heart attack.

article thumbnail

Identification of microRNA biomarkers simultaneously expressed in circulating extracellular vesicles and atherosclerotic plaques

Frontiers in Cardiovascular Medicine

The early detection of plaques by circulating biomarkers is highly clinically relevant to prevent the occurrence of major complications such as stroke or heart attacks. BackgroundAtherosclerosis is a widespread disorder of the cardiovascular system.

Plaque 52
article thumbnail

Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance

DAIC

fold higher risk for major adverse cardiac events (MACE) Caristo's AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients. fold higher risk for cardiac mortality and 5.5-fold

article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% vs. 13.2%, respectively).

article thumbnail

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction

DAIC

The promising results of the study confirm the potential of our therapy to provide an effective one-off solution to prevent heart failure progression in AMI patients,” said Matthieu de Kalbermatten , CEO, CellProthera.